Generation Bio Co. (GBIO)
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Address
301 BINNEY STREET
CAMBRIDGE, MA 02142
Founded
2016
Number of Employees
174
Website
http://www.generationbio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)